Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02648711
Title Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cerulean Pharma Inc.

Advanced Solid Tumor




Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
START Midwest/Cancer & Hematology Centers of Western Michigan, PC Grand Rapids Michigan 49503 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
South Texas Accelerated Research Therapeutics (START), LLC San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from for the field